Hologic, Inc. (HOLX)

In the past six months, Hologic's stock has seen significant activity, gaining 15.9% and outperforming its industry and sector. A major event was the proposed $18.3 billion take-private deal by Blackstone and TPG, announced in October 2025, with shareholders to receive $76 per share in cash plus a contingent value right. Hologic's stock also reached a 52-week high of $75.34 on December 15, 2025. In January 2026, Hologic announced its financial results for the fiscal first quarter ended December 27, 2025, reporting revenue of $1.047.8 million, a 2.5% increase year-over-year, but this fell short of Wall Street's estimates.

Specific detailed seasonality for all of Hologic's products and services is not explicitly outlined, but quarterly reports indicate some cyclical trends within specific segments. External factors can also influence demand, such as lower HIV testing in Africa and a physician strike in South Korea. Overall, the demand for Hologic's portfolio of products and services has been described as strong, with solid visibility into gantry orders.

Hologic, Inc. is a medical technology company focused on women's health, operating in the healthcare sector within the medical devices and supplies industry. The company develops, manufactures, and supplies diagnostic products, medical imaging systems, and surgical products globally, structured around four main segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Major products include Aptima molecular diagnostic assays, the ThinPrep System, the Rapid Fetal Fibronectin Test, solutions for breast cancer care including the Genius™ 3D Mammography™ system, hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, laparoscopic tissue ablation systems and tools, and products like the Horizon DXA and Fluoroscan Insight FD mini C-arm.

Hologic, Inc. has a global presence, developing and supplying its products for women's health worldwide. The company operates in Europe, the Americas, and Asia-Pacific, serving healthcare providers and patients in over 130 countries.

Hologic maintains a strong brand reputation as a "global champion of women's health," recognized for its commitment to improving and saving lives through early detection and proactive treatment. In the past year, Hologic has received several accolades, including being listed in "America's Best-In-State Companies (2026)" and "World's Best Employers (2025)." No specific events negatively affecting Hologic's brand reputation in the past year were found.

Hologic, Inc. has a diverse ownership structure, with institutional investors holding approximately 57.55% of the company's stock. Major institutional owners include Vanguard Group Inc, T. Rowe Price Investment Management, Inc., and BlackRock, Inc. Insiders own about 1.43% of the stock, while public companies and individual investors hold approximately 41.02%.